General Information of Drug (ID:
DR1082) |
Drug Name |
Mibefradil
|
Synonyms |
Mibefradil; Mibefradil (INN); Mibefradil HCl; Mibefradil [INN:BAN]; Posicor; (1S-cis)-2-(2-((3-(1H-Benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl methoxyacetate; 116644-53-2; 2-(2-((3-(1H-Benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl methoxyacetate (1S-cis)-; 27B90X776A; AC1L1TOE; C29H38FN3O3; CHEBI:6920; CHEMBL45816; MLS001056800; UNII-27B90X776A; HBNPJJILLOYFJU-VMPREFPWSA-N
|
Indication |
Essential hypertension
[ICD11: BA00]
|
Phase 4
|
[1]
|
Structure |
|
|
3D MOL
|
2D MOL
|
Pharmaceutical Properties |
Molecular Weight |
495.6 |
Topological Polar Surface Area |
67.4 |
Heavy Atom Count |
36 |
Rotatable Bond Count |
12 |
Hydrogen Bond Donor Count |
1 |
Hydrogen Bond Acceptor Count |
6 |
Cross-matching ID |
- PubChem CID
- 60663
- PubChem SID
-
9431
; 7979984
; 8186987
; 11111472
; 14933121
; 14933122
; 26755047
; 43118024
; 46504498
; 47276715
; 48416277
; 50064211
; 50110875
; 51068792
; 53788328
; 53801058
; 57314055
; 85788182
; 90340964
; 96024905
; 103229908
; 104011327
; 104321323
; 117509413
; 124749965
; 128037075
; 134338995
; 135047604
; 137006402
; 142794297
; 160964663
; 163620961
; 163686283
; 176250376
; 179149650
; 185998774
; 198963086
; 215784885
; 223440331
; 223554765
; 225039582
; 226424915
; 242060284
; 250133489
; 251971143
; 252479748
; 252655656
- ChEBI ID
-
- CAS Number
-
- TTD Drug ID
- D0W8XT
- Formula
- C29H38FN3O3
- Canonical SMILES
- CC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F
- InChI
- 1S/C29H38FN3O3/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28,36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26/h5-6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32)/t28-,29-/m0/s1
- InChIKey
- HBNPJJILLOYFJU-VMPREFPWSA-N
|
|
|
|
|
|
|
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.